The Effects of Inositol on Glucose Metabolism in Patients with Metabolic Syndrome At Risk of Cardiac Fibrosis

Last updated: February 18, 2025
Sponsor: Lo.Li.Pharma s.r.l
Overall Status: Active - Recruiting

Phase

N/A

Condition

Metabolic Syndrome

Diabetes Prevention

High Cholesterol (Hyperlipidemia)

Treatment

Inositol and alpha-lactalbumin

Clinical Study ID

NCT05689710
CARDIO_INO22
  • All Genders

Study Summary

The study aims to evaluate the effects of an oral supplementation based on inositols and alpha-lactalbumin on principals metabolic parameters in patients with metabolic syndrome at risk of cardiac fibrosis

Eligibility Criteria

Inclusion

At least 3 of the following inclusion criteria:

  • triglycerides levels ≥ 150 mg/dL

  • HDL ≤ 40 mg/dL

  • Fasting glycemia > 100 mg/dL <126 mg/dl

  • Systolic Pressure ≥ 130 mmHg or Diastolic pressure ≥ 85 mmHg

  • Hip circumference > 102 cm in men or 88 cm in women

Study Design

Total Participants: 30
Treatment Group(s): 1
Primary Treatment: Inositol and alpha-lactalbumin
Phase:
Study Start date:
December 23, 2022
Estimated Completion Date:
January 31, 2026

Connect with a study center

  • UOC Medicina Interna e Nefrologia P.O. AQ

    L'Aquila,
    Italy

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.